Headache Clinical Trials

Find Headache Clinical Trials Near You

Efficacy of Scalp Block in Managing Post Subarachnoid Hemorrhage Headache in Critically Ill Patients. A Single Centre Randomized Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Other, Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Subarachnoid hemorrhage (SAH) is a devastating neurological disorder associated with significant mortality and morbidity rates, arising not just from the hemorrhage itself but also because of the catastrophic multisystem sequelae that can accompany the condition. Rupture of an intracranial aneurysm accounts for up to 85% of instances of SAH, occurring in approximately 3 to 25 people per 100,000 annually in most populations. Treatment of aneurysmal SAH (aSAH) includes prevention of re-bleeding, evacuation of space-occupying hematomas, management of hydrocephalus, and prevention of secondary cerebral insult. Severe headache is the predominant characteristic symptom of aSAH, developing almost instantaneously at ictus in 50% of cases and continuing into the first days. Its severity has a variety of physiological and psychological effects on the patient. Scalp blocks have been suggested to alleviate this headache in case series. However, there is no strong evidence supporting this intervention. In this study, we aim to assess the impact of scalp blocks on headache reduction in patients undergoing endovascular treatment of an aneurysm (coiling or flow diversion) with aneurysmal subarachnoid bleeding.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• All adults \> 18 years who are admitted to the Surgical Intensive Care Unit (SICU) with a confirmed diagnosis of aneurysmal subarachnoid hemorrhage, undergoing endovascular treatment of the aneurysm (coiling/flow diversion).

Locations
Other Locations
Qatar
Hamad Medical Corporation
RECRUITING
Doha
Contact Information
Primary
Sohel Mohamed Ahmed, Consultant
SAhmed65@hamad.qa
+97450586481
Backup
Abdelrahman Balal, Clinical Fellow
abalal@hamad.qa
+97455993382
Time Frame
Start Date: 2025-10-22
Estimated Completion Date: 2026-12-30
Participants
Target number of participants: 22
Treatments
Experimental: Intervention arm (Scalp Block with Levobupivacaine)
Patients randomized to the intervention group will receive a scalp block using 20 ml of 0.5% Levobupivacaine after endovascular intervention and before extubation. In addition to conventional pain managment
Active_comparator: Control arm
Patients in the control group will receive no scalp block. Only conventional pain management will be given
Sponsors
Leads: Hamad Medical Corporation

This content was sourced from clinicaltrials.gov